Patent · US Active

Combination therapy for the treatment of mastocytosis

US12102620B2 · kind B2 · utility

0Cited by

104References

12Claims

0Family size

Assignee

Deciphera Pharmaceuticals, LLC · US

Inventors

Daniel L. Flynn · Lawrence, US
Bryan D. Smith · Madison, US
Anu Gupta · Waltham, US

Key dates

Filing date	Jul 30, 2020
Grant date	Oct 1, 2024
Priority date	—
Expiry date	Oct 10, 2042

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P43/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present disclosure relates to the use of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea or 1-(5-(7-amino-1-ethyl-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-4-bromo-2-fluorophenyl)-3-phenylurea, or a pharmaceutically acceptable salt thereof, in combination with a MAPKAP pathway inhibitor such as for example a RAS, RAF, MEK, or ERK inhibitor for the treatment of mastocytosis.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.